
Sign up to save your podcasts
Or


Dr. Christina Wiedl, director of the pediatric and young adult stem cell transplant program at Virginia Commonwealth University, presents information on the recently approved drug in oncology, keytruda for relapsed and refractory classical Hodgkin lymphoma in pediatric and young adult patients.
 By American Society of Clinical Oncology (ASCO)
By American Society of Clinical Oncology (ASCO)4.5
3131 ratings
Dr. Christina Wiedl, director of the pediatric and young adult stem cell transplant program at Virginia Commonwealth University, presents information on the recently approved drug in oncology, keytruda for relapsed and refractory classical Hodgkin lymphoma in pediatric and young adult patients.

978 Listeners

320 Listeners

496 Listeners

40 Listeners

18 Listeners

57 Listeners

283 Listeners

3,342 Listeners

676 Listeners

1,155 Listeners

44 Listeners

365 Listeners

57 Listeners

188 Listeners

43 Listeners